Home > Cardiology > ESC 2020 > Late-Breaking Science > Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients

Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients

Presented By
Prof. William Hiatt, University of Colorado, USA
Conference
ESC 2020
Trial
VOYAGER PAD trial
A new subanalysis from the VOYAGER PAD trial showed that rivaroxaban significantly reduced the risk of adverse limb ischaemia and cardiovascular events in patients with coronary artery disease (CAD) concomitant to symptomatic peripheral artery disease (PAD) after peripheral artery revascularisation [1]. Safety in the CAD subgroup of patients in this trial was also favourable. Initial results from the multicentre, randomised, double-blind VOYAGER PAD trial (n=6,564) were recently published in the New England Journal of Medicine [2]. The subanalysis presented at the ESC Congress 2020 by Prof. William Hiatt (University of Colorado, USA) focused on the patients with concomitant CAD (n=2,067). Patient characteristic analysis revealed that the subgroup of patients who had CAD were more likely to have concomitant carotid disease and heart failure, were older, ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on